DSM Biologics signs contract with first-in-class antibody developer
Groningen/Waltham –DSM Biologics has signed a contract to produce Waltham-based NKT Therapeutics Inc’s preclinical lead product iNKT mAb. DSM Biologics will be responsible for process development and cGMP manufacturing of the antibody that targets so-called CD1d-dependent natural killer T cells. Depletion of this rare subpopulation of immune modulators has been shown to reduce atherosclerosis in two different mouse models of the disease. CD1d is an antigen-presenting molecule that triggers a strong pro-inflammatory response (mediated by release of the cytokines IL-2, IFN-gamma, TNF-alpha, and IL-4) upon binding of viral and bacterial lipids and glycolipds. NKT Therapeutics develops antibodies that mediate activation or inactivation of the poorly understood immune modulator. The private firm aims to develop treatments that modulate autoimmunity and fight cancer with this approach.